"L’Institut de Cancérologie de l’Ouest (ICO) est un Centre de Lutte Contre le Cancer qui a pour mission le soin, la recherche et l’enseignement.Du diagnostic rapide à la chirurgie, la chimiothérapie, la radiothérapie, la prise en charge s'étend également aux soins de support. Spécialisés en cancérologie, les professionnels de l'ICO accompagnent les patients à toutes les étapes de leur parcours de soins, de manière personnalisée, innovante et multidisciplinaire. Consultations sans dépassement d..."

During the past decade, Centre Paul Papin conducted 300 clinical trials. In the 10-year time frame, 300 clinical trials started and 64 clinical trials were completed, i.e. on average, 21.3% percent of trials that started reached the finish line to date. In the past 5 years, 138 clinical trials started and 34 clinical trials were completed. i.e. 24.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Paul Papin" #1 sponsor was "Institut Cancerologie de l'Ouest" with 71 trials, followed by "UNICANCER" with 67 trials sponsored, "Hoffmann-La Roche" with 38 trials sponsored, "Centre Leon Berard" with 33 trials sponsored and "ARCAGY/ GINECO GROUP" with 33 trials sponsored. Other sponsors include 260 different institutions and companies that sponsored additional 99 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Paul Papin" #1 collaborator was "National Cancer Institute, France" with 17 trials as a collaborator, "AstraZeneca" with 16 trials as a collaborator, "Merck Sharp & Dohme LLC" with 11 trials as a collaborator, "Fondation ARC" with 9 trials as a collaborator and "Hoffmann-La Roche" with 9 trials as a collaborator. Other collaborators include 255 different institutions and companies that were collaborators in the rest 176 trials.

According to Clinical.Site data, the most researched conditions in "Centre Paul Papin" are "Breast Cancer" (57 trials), "Prostate Cancer" (28 trials), "Metastatic Breast Cancer" (22 trials), "Ovarian Cancer" (20 trials) and "Colorectal Cancer" (16 trials). Many other conditions were trialed in "Centre Paul Papin" in a lesser frequency.

Most popular intervention types in "Centre Paul Papin" are "Drug" (349 trials), "Procedure" (68 trials), "Radiation" (59 trials), "Other" (57 trials) and "Biological" (31 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Bevacizumab" (22 trials), "Paclitaxel" (21 trials), "Gemcitabine" (17 trials) and "Docetaxel" (16 trials). Other intervention names were less common.

The vast majority of trials in "Centre Paul Papin" are 323 trials for "All" genders, 121 trials for "Female" genders and 51 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Paul Papin". 6 are not yet recruiting, 106 are recruiting, 87 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 218 completed trials in Centre Paul Papin, 4 suspended trials, and 46 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Paul Papin, 58 "Phase 1" clinical trials were conducted, 191 "Phase 2" clinical trials and 151 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 88 trials that are defined as “Not Applicable".